文献速递艾滋病与性传播感染

人类免疫缺陷病毒感染者端粒长度在抗逆转录病毒治疗开始前下降,病毒抑制后不再下降:一项超过17年的纵向研究

Telomere Length Declines in Persons With Human Immunodeficiency Virus Before Antiretroviral Therapy Start but Not After Viral Suppression: A Longitudinal Study Over >17 Years.
PubMed 文献 · J Infect Dis · 2022-01-01

研究纳入瑞士HIV队列研究中107例有治疗前和治疗中纵向样本的参与者,用定量PCR测外周血单核细胞端粒长度。未治疗期(中位观察7.7年)端粒长度显著下降(中位-2.12%/年,P=0.002);抑制性抗逆转录病毒治疗期(中位9.8年)无端粒长度下降或增加证据(中位+0.54%/年,P=0.329)。端粒长度多基因风险评分与端粒长度变化相关(全局P=0.019),个别抗逆转录病毒药物无贡献(均P>0.15)。

要点

  • 未治疗HIV感染期端粒长度显著下降,中位-2.12%/年(P=0.002)。
  • 抑制性抗逆转录病毒治疗期端粒长度无显著变化,中位+0.54%/年(P=0.329)。
  • 端粒长度多基因风险评分与端粒长度变化相关(全局P=0.019),个别抗逆转录病毒药物无贡献(均P>0.15)。

核心结论

  • 在HIV感染者中,端粒长度与个体多基因风险评分相关;未治疗的慢性HIV感染期间端粒长度显著下降,而抑制性抗逆转录病毒治疗期间端粒长度无变化。

研究设计与样本

  • 研究测量了107名瑞士HIV队列研究参与者的外周血单核细胞端粒长度变化,这些参与者具有抑制性抗逆转录病毒治疗前和治疗期间的纵向样本。
  • 研究采用混合效应多水平回归获得纵向端粒长度动态的单变量和多变量估计,包括年龄、性别和CD4/CD8比值。
  • 研究评估了(1)个体抗逆转录病毒药物和(2)个体端粒长度多基因风险评分(基于239个单核苷酸多态性)对端粒长度的影响,样本来自先前纵向研究的798名额外参与者。

主要发现

  • 在未治疗的HIV感染期间(中位观察7.7年,四分位距4.7-11年),端粒长度显著下降(中位-2.12%/年;四分位距-3.48%至-0.76%/年;P=0.002)。
  • 在抑制性抗逆转录病毒治疗期间(中位观察9.8年,四分位距7.1-11.1年),无端粒长度下降或增加的证据(中位+0.54%/年;四分位距-0.55%至+1.63%/年;P=0.329)。
  • 端粒长度多基因风险评分对端粒长度变化有贡献(全局P=0.019),但个别抗逆转录病毒药物无贡献(所有P>0.15)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In people with human immunodeficiency virus (PWH), long-term telomere length (TL) change without/with suppressive antiretroviral therapy (ART) and the contribution of genetic background to TL are incompletely understood. METHODS: We measured TL change in peripheral blood mononuclear cells by quantitative polymerase chain reaction in 107 Swiss HIV Cohort Study participants with longitudinal samples available both before and during suppressive ART. We applied mixed-effects multilevel regression to obtain uni-/multivariable estimates for longitudinal TL dynamics including age, sex, and CD4/CD8 ratio. We assessed the effect of (1) individual antiretrovirals and (2) an individual TL-polygenic risk score ([TL-PRS] based on 239 single-nucleotide polymorphisms) on TL in 798 additional participants from our previous longitudinal studies. RESULTS: During untreated human immunodeficiency virus (HIV) infection (median observation, 7.7; interquartile range [IQR], 4.7-11] years), TL declined significantly (median -2.12%/year; IQR, -3.48% to -0.76%/year; P = .002). During suppressive ART (median observation, 9.8; IQR, 7.1-11.1 years), there was no evidence of TL decline or increase (median + 0.54%/year; IQR, -0.55% to + 1.63%/year; P = .329). The TL-PRS contributed to TL change (global P = .019) but particular antiretrovirals did not (all P > .15). CONCLUSIONS: In PWH, TL is associated with an individual PRS. Telomere length declined significantly during untreated chronic HIV infection, but no TL change occurred during suppressive ART.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Schoepf IC, Thorball CW, Ledergerber B, et al. Telomere Length Declines in Persons With Human Immunodeficiency Virus Before Antiretroviral Therapy Start but Not After Viral Suppression: A Longitudinal Study Over >17 Years. J Infect Dis. 2022. PMID: 34910812. doi:10.1093/infdis/jiab603

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。